The extended license covers implants for joint reconstruction, sports medicine, craniomaxillofacial and thoracic applications, according to a Feb. 8 news release. It includes license and development fees costing $1.5 million and contingent milestone payments of $7.5 million.
The agreement does not cover spine and dental applications that will be spun off into ZimVie.
The partnership began in September 2019 to develop orthopedic trauma implants with the Bactiguard technology, which helps prevent postoperative infections, according to the release.
